Fig. 2.

Enhanced anti-proliferative effects following combined PRMT5 and PARP inhibition in breast cancer cell lines. A, Average growth death index of breast cancer cell lines treated with the combination of a double titration of GSK3326595 and niraparib. Cell lines were treated with the combination for 10 days and cell growth was determined by CTG (n = 3 per cell line). B, Average excess over Bliss synergy scores calculated from growth inhibition of breast cancer cell lines treated with a double titration of GSK3326595 and niraparib. Values ≥ 10 are considered synergy and values ≤-10 considered antagonism. (n = 3 per cell line) C, Average excess of HSA synergy scores of breast cancer cell lines treated with a double titration of GSK3326595 and niraparib. Values ≥ 10 are considered synergy and values ≤-10 considered antagonism. (n = 3 per cell line)